优化铁蛋白正常下限对缺铁诊断与治疗模式的影响:一项基于电子健康档案的前后干预研究
本研究评估Rochester Regional Health将铁蛋白正常下限从女性10 ng/mL、男性22 ng/mL统一提高至30 ng/mL后对缺铁诊断和治疗的影响。回顾性队列比较干预前后各1.5年铁蛋白<30 ng/mL的患者,发现IDWA或IDA诊断率从51.0%升至58.5%(RR 1.15;CI: 1.12-1.17;p<0.001),口服和静脉铁剂处方及内镜检查增加,女性获益更明显。
要点
- 提高铁蛋白正常下限至30 ng/mL使IDWA/IDA诊断率提高15%。
- 女性诊断率提升幅度大于男性(RR 1.17 vs 1.06)。
- 口服和静脉铁剂处方分别增加15%和17%,内镜检查增加23%。
核心结论
- 将铁蛋白正常下限提高至基于证据的、性别无关的30 ng/mL可显著改善缺铁特别是女性及无贫血患者的识别与治疗。
主要发现
- IDWA或IDA诊断率从51.0%升至58.5%(RR 1.15;CI: 1.12-1.17;p<0.001)。
- 女性诊断率从49.4%升至58.0%(RR 1.17;CI: 1.14-1.21),男性从57.0%升至60.2%(RR 1.06;CI: 1.01-1.11)。
- IDWA诊断率增加47%(RR 1.47;CI: 1.38-1.57),IDA增加7%(RR 1.07;CI: 1.04-1.10)。
- 口服和静脉铁剂处方分别增加15%和17%,内镜检查增加23%。
- 外科部门IDWA/IDA诊断率相对增幅最高(RR 1.34;95% CI: 1.21-1.49)。
关键数值与推荐
- 铁蛋白正常下限从女性10 ng/mL、男性22 ng/mL统一提高至30 ng/mL。
- 干预后3-6个月随访铁蛋白平均差异为6.9 ng/mL(95% CI: 5.7-8.1),女性8.2 ng/mL(95% CI: 6.9-9.5),男性4.0 ng/mL(95% CI: 1.4-6.6)。
临床怎么用
- 临床可考虑采用性别无关的30 ng/mL铁蛋白正常下限以提高缺铁诊断率,尤其对女性患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron deficiency, with or without anemia (IDA or IDWA, respectively), is one of the most prevalent and underdiagnosed conditions globally, particularly in women. In September 2023, Rochester Regional Health (RRH) increased the lower limit of normal (LLN) for ferritin from 10 ng/mL in women and 22 ng/mL in men to a unified threshold of 30 ng/mL, aligning with emerging consensus guidelines. This study evaluates the impact of this clinical laboratory intervention on IDWA/IDA diagnosis and treatment patterns. We conducted a retrospective cohort study using Epic's SlicerDicer tool, comparing patients with ferritin levels < 30 ng/mL during two 1.5-year periods before and after ferritin LLN update. Primary outcome was the rate of IDWA or IDA diagnoses. Secondary outcomes included individual diagnosis rates, rates of IDWA or IDA diagnosis in males and females, iron prescriptions, hematology referrals, number of patients undergoing endoscopy procedures, and number of packed red blood cells (pRBCs) transfusions. Relative risks (RR) with multiplicity corrected confidence intervals (CI) were calculated for the primary and secondary outcomes. Subgroup analyses were stratified by sex, age, race, ferritin levels, and ordering department. Changes in mean ferritin and hematocrit levels at 3-6 months post-test were also compared using Welch's t-test. Among patients with ferritin levels < 30 ng/mL, 22 478 were identified in the pre-intervention period and 27 699 in the post-intervention period. The rate of IDWA or IDA diagnosis increased from 51.0% to 58.5% (RR 1.15; CI: 1.12-1.17; p < 0.001). This increase was more pronounced among females (49.4% to 58.0%; RR 1.17; CI: 1.14-1.21) compared to males (57.0% to 60.2%; RR 1.06; CI: 1.01-1.11). Diagnoses of IDWA rose by 47% (RR 1.47; CI: 1.38-1.57), while IDA increased by 7% (RR 1.07; CI: 1.04-1.10). Prescriptions for oral and IV iron increased by 15% and 17%, respectively, while endoscopy procedures increased by 23%. Among department specialties, surgical departments had the highest relative increase in IDWA/IDA diagnosis rates (RR 1.34; 95% CI: 1.21-1.49). Ferritin levels increased more substantially after the intervention at the 3-6-month follow-up (mean difference: 6.9 ng/mL; 95% CI: 5.7-8.1), with a more pronounced rise among females (mean difference: 8.2 ng/mL; 95% CI: 6.9-9.5) compared to males (mean difference: 4.0 ng/mL; 95% CI: 1.4-6.6). Hematocrit levels showed a modest increase in both periods, though the differences were not clinically significant. Transitioning to an evidence-based higher, sex-independent ferritin LLN significantly improved the identification and treatment of iron deficiency, particularly among women and non-anemic patients. These findings support broader adoption of revised ferritin thresholds to enhance early detection and intervention for iron deficiency in clinical practice.
引用
- Abdelhay A, Reghis M, Salhab T, et al. Impact of Optimizing the Lower Limit of Normal for Ferritin on Iron Deficiency Diagnosis and Treatment Patterns: A Pre and Post-Intervention Study Using EHR Data. Am J Hematol. 2026. PMID: 41492948. doi:10.1002/ajh.70198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。